SMS Pharmaceuticals Limited (SMSPHARMA.NS)

INR 209.77

(-8.0%)

Long Term Debt Summary of SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited's latest annual long term debt in 2023 was 1.22 Billion INR , up 0.28% from previous year.
SMS Pharmaceuticals Limited's latest quarterly long term debt in 2024 Q1 was - INR , down -100.0% from previous quarter.
SMS Pharmaceuticals Limited reported annual long term debt of 1.21 Billion INR in 2022, down -19.7% from previous year.
SMS Pharmaceuticals Limited reported annual long term debt of 1.51 Billion INR in 2021, down -0.19% from previous year.
SMS Pharmaceuticals Limited reported quarterly long term debt of 1.22 Billion INR for 2023 Q4, down 0.0% from previous quarter.
SMS Pharmaceuticals Limited reported quarterly long term debt of 1.22 Billion INR for 2023 FY, up 0.28% from previous quarter.

Annual Long Term Debt Chart of SMS Pharmaceuticals Limited (2023 - 2004)

Historical Annual Long Term Debt of SMS Pharmaceuticals Limited (2023 - 2004)

Year	Long Term Debt	Long Term Debt Growth
2023	1.22 Billion INR	0.28%
2022	1.21 Billion INR	-19.7%
2021	1.51 Billion INR	-0.19%
2020	1.51 Billion INR	108.08%
2019	730 Million INR	23.81%
2018	589.6 Million INR	-17.42%
2017	713.98 Million INR	-21.28%
2016	907 Million INR	-19.89%
2015	1.13 Billion INR	37.6%
2014	822.86 Million INR	18.62%
2013	693.69 Million INR	29.34%
2012	536.35 Million INR	-34.47%
2011	818.42 Million INR	-56.26%
2010	1.87 Billion INR	14.57%
2009	1.63 Billion INR	19.0%
2008	1.37 Billion INR	49.62%
2007	917.29 Million INR	47.54%
2006	621.71 Million INR	-4.95%
2005	654.08 Million INR	4.11%
2004	628.23 Million INR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	- INR	-100.0%
2023 Q4	1.22 Billion INR	0.0%
2023 FY	1.22 Billion INR	0.28%
2023 Q1	- INR	-100.0%
2023 Q2	1.13 Billion INR	0.0%
2023 Q3	- INR	-100.0%
2022 Q2	1.33 Billion INR	0.0%
2022 FY	1.21 Billion INR	-19.7%
2022 Q3	- INR	-100.0%
2022 Q4	1.21 Billion INR	0.0%
2022 Q1	- INR	-100.0%
2021 Q4	1.51 Billion INR	0.0%
2021 Q1	- INR	-100.0%
2021 FY	1.51 Billion INR	-0.19%
2021 Q2	1.3 Billion INR	0.0%
2021 Q3	- INR	-100.0%
2020 Q3	- INR	-100.0%
2020 Q1	- INR	-100.0%
2020 FY	1.51 Billion INR	108.08%
2020 Q4	1.51 Billion INR	0.0%
2020 Q2	984.67 Million INR	0.0%
2019 Q4	730 Million INR	0.0%
2019 Q3	- INR	-100.0%
2019 Q2	632.16 Million INR	0.0%
2019 FY	730 Million INR	23.81%
2018 FY	589.6 Million INR	-17.42%
2018 Q4	589.6 Million INR	0.0%
2017 FY	713.98 Million INR	-21.28%
2016 Q2	1.03 Billion INR	0.0%
2016 FY	907 Million INR	-19.89%
2015 FY	1.13 Billion INR	37.6%
2015 Q4	1.13 Billion INR	0.0%
2015 Q3	- INR	-100.0%
2015 Q2	1.07 Billion INR	0.0%
2015 Q1	- INR	-100.0%
2014 Q2	628.2 Million INR	0.0%
2014 Q1	- INR	-100.0%
2014 FY	822.86 Million INR	18.62%
2014 Q4	822.86 Million INR	0.0%
2014 Q3	- INR	-100.0%
2013 Q1	- INR	-100.0%
2013 Q4	693.69 Million INR	0.0%
2013 Q3	- INR	-100.0%
2013 Q2	481.63 Million INR	0.0%
2013 FY	693.69 Million INR	29.34%
2012 Q4	536.35 Million INR	0.0%
2012 FY	536.35 Million INR	-34.47%
2011 FY	818.42 Million INR	-56.26%
2011 Q4	818.42 Million INR	0.0%
2010 FY	1.87 Billion INR	14.57%
2009 FY	1.63 Billion INR	19.0%
2008 FY	1.37 Billion INR	49.62%
2007 FY	917.29 Million INR	47.54%
2006 FY	621.71 Million INR	-4.95%
2005 FY	654.08 Million INR	4.11%
2004 FY	628.23 Million INR	0.0%

Peer Long Term Debt Comparison of SMS Pharmaceuticals Limited

Name	Long Term Debt	Long Term Debt Difference
Abbott India Limited	367.6 Million INR	-232.117%
Cipla Limited	2.25 Billion INR	45.841%
Gland Pharma Limited	1.06 Billion INR	-14.592%
GlaxoSmithKline Pharmaceuticals Limited	64.69 Million INR	-1787.222%
Kopran Limited	166.02 Million INR	-635.34%
Marksans Pharma Limited	1.9 Billion INR	35.75%
NGL Fine-Chem Limited	7.44 Million INR	-16291.823%
Pfizer Limited	543.5 Million INR	-124.63%
Sanofi India Limited	139 Million INR	-778.319%
TTK Healthcare Limited	7.98 Million INR	-15185.627%